Related Experiment Video
Updated: May 14, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Maximizing the benefits of off-target kinase inhibitor activity
Monica Red Brewer1, William Pao
1Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, USA.
Abstract:
Investigators report the identification of novel mutant-specific inhibition of EGF receptor (EGFR) T790M by bis-indole-based inhibitors of protein kinase C using a small-molecule cancer cell line-based screening platform. This study shows the power of high-throughput drug screening in cancer cell lines and provides new lead scaffolds for optimization against resistant EGFR mutants in lung cancer.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Amplifying Signals via Enzymatic Cascade
Pharmacogenomics: Identification of New Drug Targets

